The University of Sydney, Faculty of Science, School of Psychology, Sydney Quality of Life Office, Sydney, Australia.
The University of Sydney, Faculty of Science, School of Psychology, Sydney Quality of Life Office, Sydney, Australia.
Gynecol Oncol. 2021 Nov;163(2):398-407. doi: 10.1016/j.ygyno.2021.08.022. Epub 2021 Sep 1.
The Measure of Ovarian Symptoms and Treatment (MOST-T35) is a patient-reported symptom index, developed and validated in the context of palliative chemotherapy for recurrent ovarian cancer (OC). We aimed to develop and validate a version suitable for surveillance of symptoms following first-line treatment for OC to support clinical follow-up.
In a prospective study of women following completion of first-line chemotherapy for OC, patients completed MOST-T35 every 3 months for up to 3.5 years and other patient-reported outcome measures. Construct validity (Spearman's correlations), discriminative validity (t-tests/ANOVAs assessing differences between clinically distinct groups), ability to detect clinically important symptoms (receiver operating characteristic analysis), and responsiveness (t-tests examining change) were assessed.
Data from 726 women who received ≥3 cycles of chemotherapy, did not progress within 3 months, and completed ≥one MOST-T35 were analysed. The revised version, MOST-S26, has 26 items and 5 multi-item indexes: peripheral neuropathy (MOST-NTx), disease or treatment-related (MOST-DorT), abdominal (MOST-Abdo), and psychological symptoms (MOST-Psych), and MOST-Wellbeing, plus 9 individual items. Construct validity was confirmed (r range = 0.43-0.88). Discriminative validity confirmed expected differences between groups. MOST-NTx and MOST-Psych detected improvements in peripheral neuropathy and psychological symptoms respectively, whereas MOST-Abdo detected worsening of abdominal symptoms pre-recurrence.
This study developed and validated the MOST-S26, for surveillance of women in follow-up after first-line chemotherapy for OC. MOST-S26 reliably detected improvement in symptoms of peripheral neuropathy, psychological distress and may detect symptoms of relapse. Administration of MOST-S26 in follow-up consultations could identify concerning symptoms and facilitate timely and appropriate intervention.
卵巢症状和治疗量表（MOST-T35）是一种患者报告的症状指数，在复发性卵巢癌（OC）姑息化疗的背景下开发和验证。我们旨在开发和验证一种适用于 OC 一线治疗后症状监测的版本，以支持临床随访。
在一项完成 OC 一线化疗的女性前瞻性研究中，患者每 3 个月完成一次 MOST-T35，最长达 3.5 年，并完成其他患者报告的结局测量。评估构念效度（Spearman 相关系数）、判别效度（评估临床显著组间差异的 t 检验/方差分析）、检测临床重要症状的能力（受试者工作特征分析）和反应性（检验变化的 t 检验）。
对接受≥3 个周期化疗、3 个月内未进展且完成≥1 次 MOST-T35 的 726 名女性的数据进行了分析。修订后的版本 MOST-S26 有 26 个条目和 5 个多条目指数：周围神经病变（MOST-NTx）、疾病或治疗相关（MOST-DorT）、腹部（MOST-Abdo）和心理症状（MOST-Psych），以及 MOST-幸福感，加上 9 个单独的条目。构念效度得到了确认（r 范围为 0.43-0.88）。判别效度证实了组间的预期差异。MOST-NTx 和 MOST-Psych 分别检测到周围神经病变和心理症状的改善，而 MOST-Abdo 则检测到复发前腹部症状的恶化。
本研究开发并验证了 MOST-S26，用于监测 OC 一线化疗后随访的女性。MOST-S26 可靠地检测到周围神经病变、心理困扰等症状的改善，并且可能检测到复发的症状。在随访咨询中使用 MOST-S26 可以识别令人担忧的症状，并促进及时和适当的干预。
